MolE prioritizes existing drugs with measured Staphylococcus aureus growth effects
MolE-XGBoost prioritized existing compounds. Of six tested commercially available compounds, elvitegravir, opicapone and ebastine showed measured growth-inhibitory effects on S. aureus; visomitin was a known-antimicrobial positive control. Effects varied: elvitegravir inhibited growth at 8 μg/mL, while the other two limited or delayed growth. This is an in-vitro finding, not a clinical antibiotic.
Technology: MolE molecular representation learning; XGBoost
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The primary source reports the study-specific result summarized here.
- Still unknown: Independent replication and broad deployment are not established by this review.
- AI role: A learned molecular representation and XGBoost rank candidates for experimental screening; selected compounds undergo MIC and growth-curve assays.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11986102/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary-source indexed article or abstract and bibliographic metadata reviewed; complete source scope is given in source_checks..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.